TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6839799
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (2.4 g)
Study: 31025207
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (Fractional CO2 laser + topical tioconazole 28% nail lacquer)
Study: 31025207
Drug: Topical tioconazole
Normalized name: tioconazole Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tioconazole 28% nail lacquer
Study: 30119694
Drug: Personalized chronotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized chronotherapy intervention including individually timed bright light therapy (BLT), bi-weekly tailored physical activity (PA) counseling, and general sleep hygiene education.
Study: 23095790
Drug: Docetaxel 70
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 70 mg/m² administered intravenously on day 1 of a 3-week cycle
Study: 19095213
Drug: Telavancin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telavancin (10 mg/kg IV every 24 hours)
Study: 19095213
Drug: Vancomycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (1 g IV every 12 hours)
Study: 17947266
Drug: Ophthalmic chloramphenicol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic chloramphenicol (OC)
Study: 8722072
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy (multiple daily injections)
Study: 8722072
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy (continuous subcutaneous insulin infusion)
Study: 6817944
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg sodium cromoglycate (SCG) powder delivered by Spinhaler
Study: 6817944
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg sodium cromoglycate (SCG) delivered by pressurized aerosol
Study: 28981173
Drug: Oral reflection
Normalized name: OCTINOXATE .012 mL in 6 mL / OCTISALATE .12 mL in 6 mL TOPICAL CREAM [RIMMEL LONDON MOISTURE RENEW LIPGLOSS - CORAL REFLECTION (119)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral reflection
Study: 26667921
Drug: AIT concurrent
Normalized name: AIT-034
DrugBank: AIT-034 (DB06106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIT concurrent with DIET (E+D, n=12)
Study: 25136791
Drug: Weekly remote
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly remote monitoring-driven management
Study: 22392415
Drug: Risperidone plus
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone plus Ginkgo T.D. (80 mg/day for patients under 30 kg and 120 mg/day for patients above 30 kg)
Study: 19156094
Drug: Local ozone
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local ozone therapy combined with low-frequency magnetic fields (ozonomagnetophoresis)
Study: 15665884
Drug: Methadone (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone (mean 106 mg, range 80-160)
Study: 15665884
Drug: Buprenorphine (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (16 mg sublingual)
Study: 12773357
Drug: Drug and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug and alcohol use
Study: 10759236
Drug: Thymosin-alpha1 at
Normalized name: Thymosin alpha1 (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymosin-alpha1 at a dose of 900 microg/m2 twice a week for six months
Study: 10759236
Drug: Thymosin-alpha1 treatment
Normalized name: Thymosin alpha1 (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymosin-alpha1 treatment
Study: 27395385
Drug: 10 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g/day milk-containing LNS
Study: 27395385
Drug: 20 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g/day milk-containing LNS
Study: 27395385
Drug: 40 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g/day milk-containing LNS
Study: 27395385
Drug: 20 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g/day milk-free LNS
Study: 27395385
Drug: 40 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g/day milk-free LNS
Study: 15992652
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg daily, vitamin C 1 g daily, and vitamin E 1,000 U daily
Study: 12637120
Drug: Glimepiride (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride (1 mg starting dose, titrated to 2 mg and 4 mg)
Study: 10872928
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of 4.0 mg triamcinolone acetonide
Study: 3897044
Drug: Normal alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Normal alcohol consumption (336 ml of ethanol per week)
Study: 3897044
Drug: Decrease in
Normalized name: Titanium Dioxide 7.2 g in 100 mL / Zinc Oxide 4 g in 100 mL TOPICAL LIQUID [Decree Daily Shield Broad Spectrum SPF 30 Sunscreen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decrease in alcohol consumption from 350 ml to 70 ml per week
Study: 27227290
Drug: Teflon infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Teflon infusion set in lipohypertrophied tissue
Study: 27227290
Drug: Teflon infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Teflon infusion set in nonlipohypertrophied tissue
Study: 25027194
Drug: Nebulized fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nebulized fentanyl (4 μg/kg)
Study: 20403471
Drug: ACEI treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEI treatment at discharge
Study: 20403471
Drug: ACEI treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEI treatment at discharge in patients without heart failure with renal dysfunction
Study: 15643100
Drug: St. John's
Normalized name: St. john's wort
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: St. John's wort (SJW) 600-1800 mg for 12 weeks
Study: 12354174
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg daily for 16 weeks
Study: 9387637
Drug: Placebo medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo medicine (control)
Study: 1561022
Drug: 5.0 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 mg.kg‐1 caffeine
Study: 1561022
Drug: 2.5 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg.kg‐1 caffeine
Study: 2861907
Drug: Flunarizine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine (5 mg/day before sleep)
Study: 28399620
Drug: Linolenic‐glutathione conjugate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linolenic‐glutathione conjugate (Lin‐GSH) cream 2% before UVB irradiation
Study: 28399620
Drug: Lin‐GSH cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lin‐GSH cream 2% after irradiation
Study: 28399620
Drug: Naïve arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naïve arm (no treatment)
Study: 18068523
Drug: Omega-3 FA
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 FA supplementation (1 g eicosapentaenoic acid and 0.7 g docosahexaenoic acid daily)
Study: 17173824
Drug: Conventional consult
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional consult (CC)
Study: 9042685
Drug: Special one-year
Normalized name: segesterone
DrugBank: Segesterone (DB14584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Special one-year treatment including polyvitamins, N-acetylcysteine, and therapeutic BAL every 3 months (n = 10)
Study: 31740092
Drug: Intranasal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal fentanyl (INF) + intramuscular Ketorolac
Study: 31740092
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl (IVF) + intramuscular Ketorolac
Study: 29654308
Drug: Low-calcium dialysate
Normalized name: Dianeal Low Calcium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-calcium dialysate (LCD, 1.25 mmol/L Ca2+)
Study: 29654308
Drug: High-calcium dialysate
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-calcium dialysate (HCD, 1.5 mmol/L Ca2+)
Study: 23311688
Drug: Cinnarizine 25
Normalized name: cinnarizine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnarizine 25 mg every 12 hours
Study: 23311688
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate 200 mg every 12 hours
Study: 17165495
Drug: Pricking therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pricking therapy (pricking thyroid gland high point)
Study: 17165495
Drug: Medication (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (oral administration of tapazole)
Study: 17165495
Drug: Pricking therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pricking therapy
Study: 11031698
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (specific dosage and duration not mentioned)
Study: 11031698
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (lower doses than those used for aggressive tocolysis)
Study: 8282350
Drug: lisinopril (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: lisinopril (5, 10, or 20 mg)
Study: 8282350
Drug: metoprolol (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoprolol (50, 100, or 200 mg)
Study: 26087670
Drug: Rituximab, 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab, 1,000 mg (2 infusions, 14 days apart; repeated at 6 months if a substantial reduction in proteinuria (equal to or >25%) is seen at 6 months)
Study: 26087670
Drug: Cyclosporine (CSA),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (CSA), 3.5‐5 mg/kg/day for 6 months (continued for another 6 months if a substantial reduction in proteinuria (equal to or >25%) is seen at 6 months)
Study: 21098626
Drug: mF-G score
Approvals — FDA: no, EMA: no, PMDA: no
Description: mF-G score greater than six (hirsutism)
Study: 21098626
Drug: mF-G score
Approvals — FDA: no, EMA: no, PMDA: no
Description: mF-G score of zero
Study: 21098626
Drug: Homeostatic model
Normalized name: collagen hemostat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeostatic model assessment for insulin resistance
Study: 17446337
Drug: Denufosol tetrasodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denufosol tetrasodium (20, 40, or 60 mg) administered three times daily for 28 days
Study: 17446337
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline) administered three times daily for 28 days
Study: 9677789
Drug: Ranitidine 50
Normalized name: ranitidine 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 50 mg e.v. every six hours
Study: 7673950
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose intravenous immunoglobulin (IVIg) treatment (0.4 g/kg for five consecutive days)
Study: 2405864
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (FA) supplementation (1 mg daily) during low-dose methotrexate (MTX) therapy (median dose 7.5 mg/week)
Study: 2405864
Drug: Placebo (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (control group) during low-dose methotrexate (MTX) therapy
Study: 2405864
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (FA) supplementation (1 mg daily) during low-dose methotrexate (MTX) therapy
Study: 7431608
Drug: Polyvalent pneumococcal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyvalent pneumococcal vaccine (Pneumovax) at baseline followed by saline placebo four weeks later.
Study: 7431608
Drug: Saline followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline followed by polyvalent pneumococcal vaccine (Pneumovax).
Study: 7431608
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (10 volunteers) receiving polyvalent pneumococcal vaccine (Pneumovax).
Study: 7431608
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (diabetics and controls) receiving the vaccine.
Study: 31675664
Drug: Donepezil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (10 mg/day for 6 weeks)
Study: 23046599
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIg) as induction therapy and thereafter as monthly infusions for 26 weeks
Study: 23046599
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIg) during induction therapy
Study: 23046599
Drug: Placebo during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo during maintenance therapy
Study: 20730514
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) replacement therapy for 1 year
Study: 16858182
Drug: IV/PO moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV/PO moxifloxacin (400 mg q24 hours)
Study: 16858182
Drug: IV piperacillin-tazobactam
Normalized name: piperacillin / tazobactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV piperacillin-tazobactam (3.0/0.375 g q6 hours) +/− PO amoxicillin-clavulanate (800 mg/114 mg q12 hours)
Study: 16858182
Drug: IV piperacillin-tazobactam
Normalized name: piperacillin / tazobactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV piperacillin-tazobactam +/− PO amoxicillin-clavulanate
Study: 12482564
Drug: C. pneumoniae‐specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: C. pneumoniae‐specific IgG antibody levels
Study: 12482564
Drug: stratification by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: stratification by antibody levels
Study: 1869801
Drug: Maltodextrin containing
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrin containing oral rehydration salts (ORS) solution
Study: 1869801
Drug: WHO recommended
Normalized name: ALCOHOL 80 mL in 100 mL TOPICAL LIQUID [WHO Recommended Hand Rub]
Approvals — FDA: no, EMA: no, PMDA: no
Description: WHO recommended glucose‐ORS solution
Study: 6222704
Drug: Benzoyl peroxide
Normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzoyl peroxide (5% lotion) applied twice daily for four weeks
Study: 6222704
Drug: Hexachlorophene (3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexachlorophene (3% colloidal suspension) applied twice daily for four weeks
Study: 28643570
Drug: Therapeutic instrumental
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic instrumental music performance, 12 individual clinical contacts, twice weekly for six weeks.
Study: 11561568
Drug: Levofloxacin 300
Normalized name: Levofloxacine
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin 300 mg daily for 10 days
Study: 11561568
Drug: Ofloxacin 600
Normalized name: ofloxacin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 600 mg daily for 10 days
Study: 6197010
Drug: Vitamin B12
Normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B12 injection (Control)
Study: 29536296
Drug: Intraperitoneal paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intraperitoneal paclitaxel (60 mg/m2 on days 0, 14, 21, 28, 42, 49, and 56)
Study: 29536296
Drug: Intravenous paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous paclitaxel (80 mg/m2 on the same schedule)
Study: 1869405
Drug: Epinephrine 2%
Normalized name: Xylocaine with Epinephrine 2%-1:50,000 Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine 2% drops administered twice a day for 2 weeks
Study: 1869405
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered twice a day for 2 weeks
Study: 30239552
Drug: High-β-carotene tomato
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-β-carotene tomato juice (30.4 mg of β-carotene)
Study: 30239552
Drug: High-lycopene tomato
Normalized name: Tomato
DrugBank: Tomato (DB10573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-lycopene tomato juice (42.5 mg of lycopene)
Study: 27405054
Drug: Slow infusion
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow infusion feeding (SF)
Study: 24467807
Drug: Active common
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active common factor based treatment
Study: 20378197
Drug: Glargine insulin
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Glargine insulin therapy
Study: 17951477
Drug: Quercetin 730
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin 730 mg/d for 28 d
Study: 12572723
Drug: Ozonized sunflower
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozonized sunflower oil (Oleozon) applied twice per day for 6 weeks
Study: 12572723
Drug: Ketoconazole cream
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoconazole cream 2% (Nizoral) applied twice per day for 6 weeks
Study: 2669667
Drug: 4.6 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.6 g/d of omega-3 fatty acids
Study: 2669667
Drug: corn oil
Normalized name: Corn Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: corn oil (5.4 g/d linoleic acid)
Study: 579116
Drug: Tibric acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibric acid (1.5 g daily for 1 year)
Study: 12430146
Drug: Photodynamic Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic Therapy (PDT)
Study: 12784346
Drug: Aprepitant plus
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprepitant plus standard therapy (ondansetron 32 mg IV and dexamethasone 20 mg on Day 1; dexamethasone 8 mg twice daily on Days 2-4)
Study: 12784346
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (ondansetron 32 mg IV and dexamethasone 20 mg on Day 1; dexamethasone 8 mg twice daily on Days 2-4)
Study: 11006251
Drug: Methazolamide 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methazolamide 1% in cyclodextrin solution
Study: 8835708
Drug: Paroxetine (PAR),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (PAR), 20 mg/day
Study: 1445103
Drug: 100 mls
Normalized name: mepolizumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mls of Iopamiro 370 at 1 ml/sec scanning inferosuperiorly
Study: 1445103
Drug: 50 mls
Normalized name: chlorothiazide 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mls of Iopamiro 370 at 1 ml/sec scanning inferosuperiorly
Study: 1445103
Drug: 40 mls
Normalized name: fidaxomicin 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mls hand injected bolus followed by 60 ml pump infusion at 1.3 mls/sec scanning inferosuperiorly
Study: 31538907
Drug: Curcumin supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin supplementation (2 capsules containing 500 mg of phosphatidylcholine complex of curcumin)
Study: 31538907
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two 500 mg placebo capsules)
Study: 23054866
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition (TPN) alone for 28 days
Study: 15500091
Drug: Chemosensitivity test-guided
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemosensitivity test-guided chemotherapy
Study: 10917407
Drug: MDMA-125 mg
Normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA-125 mg
Study: 10917407
Drug: Amphetamine-40 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amphetamine-40 mg
Study: 10917407
Drug: MDMA-125 mg
Normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA-125 mg and MDMA-75 mg
Study: 9207617
Drug: Beta-blockade treatment
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockade treatment
Study: 9207617
Drug: Non-carvedilol drugs
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-carvedilol drugs
Study: 8365381
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of zinc as zinc sulphate
Study: 3510848
Drug: High-dosage oral
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dosage oral metoclopramide (three times 50 mg) with prednisone (three times 25 mg)
Study: 3510848
Drug: High-dosage oral
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dosage oral metoclopramide (three times 50 mg) without prednisone
Study: 22549281
Drug: ACE inhibition
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibition (ramipril 5 mg/day)
Study: 22549281
Drug: ARB (candesartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARB (candesartan 16 mg/day)
Study: 19513578
Drug: Kyphoplasty (5.56
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kyphoplasty (5.56 +/- 0.62 mL of PMMA)
Study: 19513578
Drug: Vertebroplasty (4.91
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vertebroplasty (4.91 +/- 0.65 mL of PMMA)
Study: 12942852
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Lutéran tablet